LTR Pharma, a clinical-stage biopharmaceutical company, is pioneering the world’s first and only intranasal technology for treating erectile dysfunction (ED). SPONTAN, LTR’s phosphodiesterase-5 (PDE-5) inhibitor, delivers results on demand—in 10 minutes or less—unlike traditional solutions that can take an hour or more to work. “ED can impact a man’s self-esteem, confidence, and mental well-being. We are treating it effectively, instantly and easily – empowering spontaneity in intimate moments,” says Lee Rodne, executive chairman. Traditional medication, ingested orally, must first pass through the digestive system before reaching the bloodstream. Many of the widely used PDE-5 inhibitors, like Viagra, can cause unpleasant side effects such as stomach issues, diarrhea, headache, flushing, dizziness, heartburn, and joint or back pain during sexual activity. Due to these drawbacks, more than 50 percent of patients discontinue oral medication— which is considered the gold standard for first-line ED treatments—within a year. SPONTAN has been clinically proven to address all these challenges. Applied intranasally, it achieves rapid absorption and a faster onset by bypassing the digestive system, providing men with greater control and confidence when it matters most. Its favorable safety profile and lower dosage also reduces the risk of side effects seen with traditional treatments, allowing men to experience greater comfort and confidence. Quick Action, Happier Times SPONTAN is a game-changer, entering the bloodstream instantly through the nasal cavity. Its efficiency is driven by the large surface area in the nasal cavity, allowing rapid drug absorption for fast results. Nasal administration also enables lower dosages than oral treatments, maximizing effectiveness while minimizing drug intake.
Clinical-Stage Biopharmaceutical
Diabetology Limited is an award-winning clinical-stage biopharmaceutical company that solves a physician’s dilemma of improving insulin effectiveness without side effects. The company discovered the possibility of delivering insulin in the form of Capsulin Oral Anti- Diabetic (OAD), an easy-to-swallow capsule to be consumed twice daily. The proprietary, versatile delivery system allows insulin and other proteins such as GLP-1 RAs to be ingested orally, bringing normalcy to the lives of diabetes patients. “Our novel oral delivery system is physiologically consistent with how the pancreas and the liver naturally control the glucose levels in our bodies,” says Dr. Roger New, co-founder of Diabetology. After extensive research, Dr. New has successfully developed a powerful capsule formulation that overcomes stomach acidity and protease attacks in the upper intestine, ultimately enhancing its availability to the body, and specifically to the liver where insulin exerts its primary activities. Capsulin OAD contains pharmacopeia-safe special excipients that activate gut cells, helping insulin to pass through the epithelium and enter the liver’s portal vein. This innovative approach significantly improves insulin delivery in a reproducible manner, lowering the risk of hypoglycemia as compared to other methods like sublingual tablets, pumps, EpiPens, and subcutaneous injections. Recent research led by Diabetology has made significant discoveries about Capsulin OAD’s ability to solve two predominant industry-plaguing challenges—cost-effectiveness and toxicity. Given the high cost of recombinant human insulin per dosage, direct delivery to the liver cells reduces the required medication, making it commercially viable. This eliminates the possibility of toxicity, which could accidentally occur while injecting it into the outer circulation. “A recent phase 2b study has demonstrated that our delivery is safe with no hypoglycemia or insulinemia. As a result, there is a positive impact on fasting plasma glucose, systolic blood pressure, triglycerides and lipid levels that play a role in the body’s cardiovascular health,” says Glen Travers, co-founder of Diabetology. .
Synthetic Biology
Halal Biopharma: Closing the Therapeutic Gaps
Dr Israfil Merican MD, MHM, General Manager, Head of Medical Affairs, Pharmaniaga Berhad
Drug Discovery and Development
Clinical Trials Landscape in APAC and Its Unique Characteristics and Opportunities
Marcia Matos, APAC Clinical Operations Hub Director, and Department of Clinical Development R&D & Ch
Clinical Trial
Clinical Operations: Challenges, Trends, Insights
Giovanni Guzzo, Sr. Clinical Country & Site Lead, Ass. Director at Biogen
Clinical-Stage Biopharmaceutical
Key Considerations for the Evolving Cell Therapy Landscape
Prue Cowin B.BiomedSci (Hons) PhD Senior Associate, Patent Attorney, FB Rice:Dr Sarah Tregenza BSc(H
Drug Discovery and Development
The simple things in life are still the best, even in clinical development
Ken Lee, General Manager and Region Head, Clinical Development, Asia Pacific, Syneos Health
IN MY OPINION
Therapeutics
Bridging the Diversity Divide
Victoria Sanjurjo, Director of Clinical Development, Ionis Pharmaceuticals, Inc [NASDAQ: IONS]
LAST WORD
Therapeutics
Improvements in Insulin Delivery Over Time and Expectations for the Future
Jesper Lekdorf, MD, Sr Medical Director, Head of Medical Affairs, Novo Nordisk, Japan
IN FOCUS
The Role of Biomarkers in Advancing Clinical-Stage Biopharmaceutical Research
Advancements in biomarker research, including liquid biopsies, companion diagnostics, and digital health technologies, are crucial for drug development and personalized medicine in the Asia-Pacific region.
Innovation And Growth In Asia's Clinical-Stage Biopharmaceutical Industry
The clinical-stage biopharmaceutical industry in the Asia-Pacific (APAC) region is witnessing remarkable growth, fueled by rising demand for innovative therapies, an expanding healthcare market, and supportive government policies.
EDITORIAL
Innovating Health and Transforming Lives with AI
AI is accelerating research timelines and improving precision by automating complex processes, making drug development faster and more cost-efficient. This not only reduces the time to market for new treatments but opens doors for innovative therapies.
Data analytics also plays a vital role in reshaping biopharma. By leveraging vast datasets, companies can optimize clinical trials, streamline drug development, and ensure regulatory compliance. In the growing market, data analytics aids in managing regulatory complexities and tailoring therapies to diverse populations. This approach enhances clinical trials, enables precision medicine, and boosts operational efficiency.
On a promise of these benefits, the global biopharmaceuticals market size is estimated to reach USD 1,183.72 billion with a CAGR of 8.5 percent by the end of 2032.
The magazine features a thought leadership article from Giovanni Guzzo, Senior Clinical Country and Site Lead and Assistant Director at Biogen who emphasizes on the importance of AI as a solution for global clinical trials and emphasizes the need for careful planning, local collaborations, and open communication with healthcare professionals. It also features an article from Dr. Israfil Merican, MD, MHM, Assistant Vice President - Head of Medical Affairs and Bioequivalence at Pharmaniaga Berhad who emphasizes on the need for collaboration between governments, industry players and healthcare professionals to develop halal-certified medicines, addressing a gap in care for Muslim patients.
In this edition of Life Sciences Review APAC, we also bring you the story of APAC's Top Clinical Stage Biopharmaceutical Company 2025, delivering valuable insights and solutions leading the companies to make informed decisions and giving them a competitive advantage. One of them is LTR Pharma, which focuses on improving men’s health physically and mentally through the commercialization of an innovative, safer and more spontaneous alternative to oral medications.
We hope we find you the right partner to meet your organization’s needs.
Let us know your thoughts!
